The stock price of Bausch Health Companies Inc (NYSE: BHC) has surged by 1.47 when compared to previous closing price of 6.79, but the company has seen a -4.44% decline in its stock price over the last five trading sessions. seekingalpha.com reported 2025-02-21 that Bausch + Lomb reported solid Q4 and full-year 2024 earnings, with CEO Brent Saunders highlighting positives while avoiding the critical issue of Bausch Health’s potential sale of its 88% stake. The company’s performance review for 2024 was strong, but the future share price trajectory hinges on whether Bausch Health will divest its majority ownership. Investors are closely watching Bausch Health’s decision, as it remains the key factor influencing Bausch + Lomb’s market valuation and investor sentiment.
Is It Worth Investing in Bausch Health Companies Inc (NYSE: BHC) Right Now?
The 36-month beta value for BHC is also noteworthy at 0.40. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 5 rating it as “hold,” and 0 rating it as “sell.”
The public float for BHC is 289.91M, and at present, short sellers hold a 2.68% of that float. The average trading volume of BHC on March 14, 2025 was 2.51M shares.
BHC’s Market Performance
BHC stock saw an increase of -4.44% in the past week, with a monthly gain of 8.16% and a quarterly increase of -18.56%. The volatility ratio for the week is 3.42%, and the volatility levels for the last 30 days are 3.96% for Bausch Health Companies Inc (BHC). The simple moving average for the last 20 days is -2.11% for BHC stock, with a simple moving average of -5.10% for the last 200 days.
Analysts’ Opinion of BHC
Many brokerage firms have already submitted their reports for BHC stocks, with Piper Sandler repeating the rating for BHC by listing it as a “Underweight.” The predicted price for BHC in the upcoming period, according to Piper Sandler is $3 based on the research report published on August 02, 2024 of the previous year 2024.
Raymond James, on the other hand, stated in their research note that they expect to see BHC reach a price target of $8. The rating they have provided for BHC stocks is “Mkt Perform” according to the report published on July 10th, 2024.
Jefferies gave a rating of “Buy” to BHC, setting the target price at $16 in the report published on September 20th of the previous year.
BHC Trading at -5.25% from the 50-Day Moving Average
After a stumble in the market that brought BHC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -39.88% of loss for the given period.
Volatility was left at 3.96%, however, over the last 30 days, the volatility rate increased by 3.42%, as shares surge +8.33% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -9.93% lower at present.
During the last 5 trading sessions, BHC fell by -4.44%, which changed the moving average for the period of 200-days by +8.50% in comparison to the 20-day moving average, which settled at $7.04. In addition, Bausch Health Companies Inc saw -14.52% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BHC starting from Carson Seana, who sale 440 shares at the price of $8.35 back on Dec 02 ’24. After this action, Carson Seana now owns 433,066 shares of Bausch Health Companies Inc, valued at $3,674 using the latest closing price.
Carson Seana, the Officer of Bausch Health Companies Inc, proposed sale 440 shares at $8.35 during a trade that took place back on Dec 02 ’24, which means that Carson Seana is holding shares at $3,674 based on the most recent closing price.
Stock Fundamentals for BHC
Current profitability levels for the company are sitting at:
- 0.17 for the present operating margin
- 0.63 for the gross margin
The net margin for Bausch Health Companies Inc stands at -0.0. The total capital return value is set at 0.08.
Based on Bausch Health Companies Inc (BHC), the company’s capital structure generated 1.06 points at debt to capital in total, while cash flow to debt ratio is standing at 0.07. The debt to equity ratio resting at -16.9. The interest coverage ratio of the stock is 1.15.
Currently, EBITDA for the company is 1.55 billion with net debt to EBITDA at 7.23. When we switch over and look at the enterprise to sales, we see a ratio of 2.39. The receivables turnover for the company is 4.49for trailing twelve months and the total asset turnover is 0.36. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.86.
Conclusion
In summary, Bausch Health Companies Inc (BHC) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
